Hold Rating on Atea Pharmaceuticals: Analysis of Clinical Programs, Financial Health and Future Prospects
Atea Pharmaceuticals Analyst Ratings
Atea Pharmaceuticals (AVIR) Gets a Hold From SVB Securities
Atea Pharmaceuticals (AVIR) Gets a Hold From SVB Securities
Atea Pharmaceuticals (AVIR) Gets a Hold From J.P. Morgan
JPMorgan Adjusts Atea Pharmaceuticals Price Target to $8 From $12, Maintains Neutral Rating
JP Morgan Maintains Neutral on Atea Pharmaceuticals, Lowers Price Target to $8
SVB Securities Reaffirms Their Hold Rating on Atea Pharmaceuticals (AVIR)
SVB Securities Adjusts Atea Pharmaceuticals' Price Target to $6 From $8, Keeps Market Perform Rating
Atea Pharmaceuticals (AVIR) Receives a Hold From SVB Securities
Atea Pharmaceuticals Analyst Ratings
SVB Leerink Maintains Market Perform on Atea Pharmaceuticals, Lowers Price Target to $6
Morgan Stanley Sticks to Its Sell Rating for Atea Pharmaceuticals (AVIR)
Morgan Stanley Adjusts Price Target on Atea Pharmaceuticals to $4 From $7, Maintains Underweight Rating
Atea Pharmaceuticals Analyst Ratings
Morgan Stanley Maintains Underweight on Atea Pharmaceuticals, Lowers Price Target to $4
Atea Pharmaceuticals (AVIR) Gets a Hold From SVB Securities
SVB Securities Keeps Their Hold Rating on Atea Pharmaceuticals (AVIR)
Morgan Stanley Sticks to Its Sell Rating for Atea Pharmaceuticals (AVIR)
Atea Pharmaceuticals Price Target Raised to $7.00/Share From $6.00 by Morgan Stanley
No Data